Virbac: Jefferies still a buyer
(CercleFinance.com) - Jefferies maintains its buy rating on Virbac shares, along with its target price of 450 euros (share closed down 10% at 292 euros on Friday).
Following the strong sales performance in H1, Virbac's EBIT margin has benefitted from sales growth, despite the negative impact of inflationary headwinds, a rebound in commercial expenses and R&D spending to support future growth, the analyst said.
Jefferies notes that Virbac has maintained its FY22 guidance of 5%-10% revenue growth and an EBITA margin of around 15%.
Copyright (c) 2022 CercleFinance.com. All rights reserved.
The information and analyses distributed by Cercle Finance are only intended as decision-making support for investors. Cercle Finance's responsibility may not be entailed, either directly or indirectly following the use of such information and analyses by readers. Any non-professional investor is recommended to consult a professional advisor before making any investment decision. This indicative information in no way constitutes any invitation to sell or buy securities.
Following the strong sales performance in H1, Virbac's EBIT margin has benefitted from sales growth, despite the negative impact of inflationary headwinds, a rebound in commercial expenses and R&D spending to support future growth, the analyst said.
Jefferies notes that Virbac has maintained its FY22 guidance of 5%-10% revenue growth and an EBITA margin of around 15%.
Copyright (c) 2022 CercleFinance.com. All rights reserved.
The information and analyses distributed by Cercle Finance are only intended as decision-making support for investors. Cercle Finance's responsibility may not be entailed, either directly or indirectly following the use of such information and analyses by readers. Any non-professional investor is recommended to consult a professional advisor before making any investment decision. This indicative information in no way constitutes any invitation to sell or buy securities.